A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

Condition studied

Atopic Dermatitis

Investigational medicinal product(s)

Eligibility

Primary endpoint

Percent change from baseline in EASI at Week 24

Endpoint detail

Proportion of participants achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) and a ≥ 2-point reduction from baseline at Week 24, Incidence and severity of TEAE including treatment-emergent SAEs, Proportion of participants achieving a ≥ 75% reduction in EASI (EASI-75; which is considered as achieving clinically significant response) at Week 24, Proportion of participants achieving a ≥ 90% reduction in EASI (EASI-90), at Week 24